- Details
- Kosuke Tamekura joins Pedro Barata to discuss results from the International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) looking at outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies. Data from over 40 institutions worldwide is being collected to assess patients' demographics and outcomes. Patients with brain metastases from...
|
- Details
- Pedro Barata is joined by Christopher Ryan to discuss SWOG S0931, the EVEREST trial of everolimus as adjuvant therapy for patients with renal cell carcinoma (RCC). The authors designed a phase III, double-blind, placebo-controlled, intergroup study of the mTOR inhibitor everolimus as adjuvant therapy following resection of RCC. Everolimus is an mTOR inhibitor that is FDA-approved for treating adva...
|
- Details
- Deepak Kilari joins Pedro Barata in a discussion on the ORACLE study, which investigates the efficacy of combination systemic therapies in patients with advanced non-clear cell renal cell carcinoma. Dr. Kilari gives an overview of the trial design and shares his hopes and goals for the future of this trial as it continues to expand to more institutions and provide a larger, more robust data set. B...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Lancet publication Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Approximately 80% of patients, present initially with local regional disease. However, despite the i...
|
- Details
- Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...
|
- Details
- Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...
|
- Details
- In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...
|
- Details
- Daniel Watson and Alan Burns present their collaborative approach in favor of percutaneous renal mass cryoablation for renal masses. To date, Dr. Watson and Burns have done 207 of these procedures. The mean age of the patient is approximately 69 years and the mean size of the lesions is about 2.3 centimeters. Dr. Watson suggests a 85% cure rate with this procedure. Biographies: Daniel L. Watson, M...
|
- Details
- James Borin speaks about the revolution and the evolution of percutaneous renal surgery. The evolution of the technique is now using ultrasound guidance and smaller scopes, mini-percs with endoscopic guidance. Dr. Borin answers the following questions during his presentation: who can have a supine PCNL? What is it?, and When should it be done ambulatory? He also describes what he calls a hybrid pr...
|
- Details
- Ashley Baker presents on percutaneous renal biopsy in the ambulatory surgery center. Dr. Baker presents in favor of urologists being involved and of the safety of the procedure being performed in the ambulatory surgery center. Biographies: Ashley Baker, MD, Urology Specialist, Shreveport, Louisiana, USA. Moderator: Evan R. Goldfischer, MD, MBA Related Content: Biopsy of the Small Renal Mass - Stil...
|
